menu
    • menu
    [{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Aliada Therapeutics","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Aliada Therapeutics","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Aliada Therapeutics

    Menu

    Aliada Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aliada Therapeutics

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Aliada Therapeutics

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALIA-1758

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $1,400.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AbbVie Completes Acquisition of Aliada Therapeutics

                            Details : Through the acquisition, AbbVie will leverage Aliada's pipeline, including its lead compound, ALIA-1758, which holds the potential to be a best-in-class therapy for Alzheimer's disease.

                            Product Name : ALIA-1758

                            Product Type : Large molecule

                            Upfront Cash : $1,400.0 million

                            December 12, 2024

                            Lead Product(s) : ALIA-1758

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $1,400.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aliada Therapeutics

                            U.S.A arrow
                            European Pharma Congress
                            Not Confirmed

                            Aliada Therapeutics

                            U.S.A arrow
                            European Pharma Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALIA-1758

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $1,400.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AbbVie to buy Alzheimer's therapy developer Aliada Therapeutics for $1.4 bln

                            Details : AbbVie will acquire Aliada and it's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease.

                            Product Name : ALIA-1758

                            Product Type : Large molecule

                            Upfront Cash : $1,400.0 million

                            October 28, 2024

                            Lead Product(s) : ALIA-1758

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $1,400.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth